Exhibitor Tutorial

Charles River Exhibitor Tutorial: A perspective on the use of stem cells in high throughput screening

Tuesday, February 6
12:30 PM - 1:15 PM
Location: Room 10

A perspective on the use of stem cells in high throughput screening
Providing HTS assay solutions that find that balance between biological relevance and throughput is critical for successful drug discovery programs. In a cellular setting this not only includes considering the most applicable assay parameters and readout but also the selection of the cell line. Whilst most would agree that primary cell lines and 3D model systems are most likely to get closest to the goal of physiological relevance, the availability of cells in sufficient numbers and/or suitable assay technologies limit their application to screening of large compound collections. The use of differentiated stem cells provides a realistic alternative, providing access to large numbers of cells that are both disease and tissue type relevant, particularly for investigating disease indications where there is a clear genetic causal link.
In this tutorial we will briefly outline a wide selection of in vitro drug discovery capabilities with a focus on exemplifying our success with more challenging HTS projects. This will be achieved by describing a project to develop, validate and screen using human embryonic stem cells in a TR-FRET 384-well format assay to identify compounds that modulate mutant protein levels in a neurodegenerative disease.

Susan Desmond

Presentation(s):

Send Email for Susan Desmond

David Cronk

Director, High Throughput Screening Sciences
Charles River Laboratories

David has been with Charles River Laboratories, a provider of contract drug discovery services, since 2005 and has for HTS and the associated assay development and compound management activities. He has regular interaction with potential and existing clients to advise and discuss assay options and management of ongoing collaborations for a range of customers engaged in pharmaceutical discovery, ranging from the large pharmaceutical companies to charitable foundations.

Prior to joining Charles River David has many years’ experience in pharmaceutical research and development, both in the biotechnology and large pharma sectors. He spent approximately 15 years within the GlaxoSmithKline organisation providing assay development expertise and assay support for a number of disease related projects, before joining a biotech company focussing on analgesia drug discovery to lead their molecular pharmacology team.

Presentation(s):

Send Email for David Cronk


Assets

Charles River Exhibitor Tutorial: A perspective on the use of stem cells in high throughput screening



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Charles River Exhibitor Tutorial: A perspective on the use of stem cells in high throughput screening